+ All Categories
Home > Documents > 16 CANINE SURGERY AND MEDICINE VP SEPTEMBER 2017 Surgery of oral tumours: anything...

16 CANINE SURGERY AND MEDICINE VP SEPTEMBER 2017 Surgery of oral tumours: anything...

Date post: 24-Jun-2020
Category:
Upload: others
View: 0 times
Download: 0 times
Share this document with a friend
1
16 CANINE SURGERY AND MEDICINE VP SEPTEMBER 2017 Surgery of oral tumours: anything new? LAURENT FINDJI of Fitzpatrick Referrals examines the latest literature before looking to the future, where he says new technologies will become commonplace Figure 1. CT lymph node mapping, transverse and parasagittal views. Contrast medium was injected around an oral tumour, revealing on the subsequent CT study that the ipsilateral mandibular lymph node (arrows) is the first lymph node to drain the tumour (sentinel lymph node) [copyright L. Findji]. Figure 2. Radical bilateral maxillectomy for resection of an oral sarcoma. Clinical aspect of the tumour (a, b). The resection of the rostral maxilla was planned from a 3D-printed model of the patient’s skull (c) and extended to the carnassial teeth bilaterally (d). Despite the radical resection, the cosmetic aspect (e, f) and the function were acceptable [copyright L. Findji]. a b c d e f Laurent Findji, DMV, MS, DiplECVS, MRCVS, is a senior surgeon in oncology and soft tissue, a European Specialist in Small Animal Surgery and an RCVS Recognised Specialist in Small Animal Surgery. Laurent graduated from Paris vet school, the Ecole Nationale Vétérinaire d’Alfort, in 1995 and was assistant instructor in the anatomy department the following year. He qualified for a two-year surgical internship and later completed a Master of Science in Biology and Physiology of Circulation and Respiration, as well as a university degree in Novel Surgery and Microsurgery. He became a diplomate of the European College of Veterinary Surgeons in 2008 and was recognised as a specialist in small animal surgery by the RCVS in 2012. Laurent worked at VRCC Veterinary Referrals in Essex, from 2006 to 2014, where he was one of the full-time soft-tissue surgeons and directors. He moved to Fitzpatrick Referrals in October 2014 to form the first team for its new Soft Tissue and Oncology Service. ORAL TUMOURS ARE REGULARLY ENCOUNTERED in dogs and cats and our ability to treat them has increased over the last few decades. Although many oropharyngeal tumours are best treated with a multi- modal approach, including various combinations of surgery, radiotherapy, chemotherapy and immunotherapy, surgery remains the mainstay of their treatment. Tumour biology Like for other cancers, tumour biology is the main determinant of prognosis. Only a few tumour types constitute the vast majority of tumours encountered. In dogs, the most frequently encountered malignant tumours of the oral cavity are malignant melanomas (MM; 31 to 42% of cases), squamous cell carcinomas (SCC; 17 to 25% of cases), fibrosarcomas (FSA; 7.5 to 25% of cases) and osteosarcomas (OSA; 6 to 18% of cases). In cats, the most common oropharyngeal tumours are SCC (75% of cases) and FSA (13 to 17% of cases). Very schematically, all malignant tumours in dogs tend to be locally- invasive and require wide resection. In one study, 37 out of 120 (31%) malignant oral tumours recurred after surgical excision, with recurrence being most common with FSA (54% of cases) and least common with SCC (17% of cases). 1 Malignant melanomas recurred in 27% of cases, but had the highest metastatic rate (30%). Even higher metastatic rates (50-80%) for MM have been reported previously. In one recent study, nine of 13 dogs (69%) with MM had metastasis to locoregional lymph nodes. 2 Fibrosarcomas, OSAs and SCCs had metastatic rates of 21, 22% and 3%, respectively. 1 One- and two-year survival rates were respectively 50% and 50% for SCC, 29% and 12% for FSA, 9% and 0% for OSA and 5% and 0% for MM. 1 Prognostic factors for outcome with malignant oral tumours treated by curative-intent surgery include tumour type, completeness of resection, tumour size and patient age. 1 Local recurrence is a major negative prognostic factor, influenced by tumour type, size and location, as well as by completeness of surgical excision. Wide resections, including portions of the underlying bone(s), are therefore indicated for treatment of malignant oral tumours. How wide is wide enough depends on the tumour type and size. Tumour staging Tumour staging is a crucial step in the management of oral tumours. It involves advanced imaging to determine the location, extension and invasion of the primary tumour (T staging), imaging, mapping and biopsy of the locoregional lymph nodes (N staging) and imaging to assess the presence of distant metastasis (M staging). Over the last few years, it has appeared that the route of lymphatic drainage of the oral cavity is complex and hardly predictable. One study of 31 dogs with oral tumours which had their mandibular and retropharyngeal lymph node extirpated bilaterally showed that 62% of metastatic tumours would spread to contralateral lymph nodes, with 8% spreading exclusively contralaterally. 2 The aspect of lymph nodes cannot reliably be used to determine the usefulness of taking biopsies from them: a study evaluating 100 dogs with oral malignant melanoma showed that lymph node palpation and size are not reliable indicators (40% of normal- sized lymph nodes were positive for metastasis) of lymph node metastasis and that cytology or histology was required for accurate staging. 3 In another study involving 37 dogs and seven cats, clinical examination of the lymph node also appeared poorly correlated with their metastatic status. 4 This evidences the importance of sampling the first lymph node (“sentinel” lymph node) on the lymphatic route of drainage of the tumour. The determination of the location of this sentinel lymph node is the objective of lymph node mapping techniques (Figure 1), increasingly used in veterinary oncology. 5,6 Once identified, the sentinel lymph node is best examined after excisional biopsy (typically performed at the time of surgery), although in one study, cytological examination of lymph nodes for tumour invasion appeared 100% sensitive and 96% specific, showing that fine-needle aspiration is an accurate diagnostic tool for lymph node metastasis evaluation. 4 Surgery As discussed previously, wide surgical resection of malignant oral tumours remains the mainstay of their treatment. However, many tumours will be best treated by a multi-modal approach combining surgery with various combinations or neoadjuvant and adjuvant chemotherapy, radiotherapy, and immunotherapy. Only surgery will briefly be discussed here. Local conditions of the oral cavity (limited availability in loose soft tissues, constant movements, bacterial charge) make wide oral resections and reconstructions often challenging. A few technical specificities, such as avoiding the use of electrocautery to cut mucosal surfaces and double- layer closures, however, limit the risk of complications. Brisk haemorrhage continued on page 18
Transcript
Page 1: 16 CANINE SURGERY AND MEDICINE VP SEPTEMBER 2017 Surgery of oral tumours: anything new?fs-1.5mpublishing.com › vet › issues › 2017 › 09 › vp_2017_09... · 2017-11-21 ·

16 CANINE SURGERY AND MEDICINE VP SEPTEMBER 2017

Surgery of oral tumours: anything new?

LAURENT FINDJIof Fitzpatrick Referrals examines the latest literature before looking to the future, where he says new technologies will become commonplace

Figure 1. CT lymph node mapping, transverse and parasagittal views. Contrast medium was injected around an oral tumour, revealing on the subsequent CT study that the ipsilateral mandibular lymph node (arrows) is the first lymph node to drain the tumour (sentinel lymph node) [copyright L. Findji].

Figure 2. Radical bilateral maxillectomy for resection of an oral sarcoma. Clinical aspect of the tumour (a, b).

The resection of the rostral maxilla was planned from a 3D-printed model of the patient’s skull (c) and extended to the carnassial teeth bilaterally (d). Despite the radical resection, the cosmetic aspect (e, f) and the function were acceptable [copyright L. Findji].

a b

c

d

e

f

Laurent Findji, DMV, MS, DiplECVS, MRCVS, is a senior surgeon in oncology and soft tissue, a European Specialist in Small Animal Surgery and an RCVS Recognised Specialist in Small Animal Surgery. Laurent graduated from Paris vet school, the Ecole Nationale Vétérinaire d’Alfort, in 1995 and was assistant instructor in the anatomy department the following year. He qualified for a two-year surgical internship and later completed a Master of Science in Biology and Physiology of Circulation and Respiration, as well as a university degree in Novel Surgery and Microsurgery. He became a diplomate of the European College of Veterinary Surgeons in 2008 and was recognised as a specialist in small animal surgery by the RCVS in 2012. Laurent worked at VRCC Veterinary Referrals in Essex, from 2006 to 2014, where he was one of the full-time soft-tissue surgeons and directors. He moved to Fitzpatrick Referrals in October 2014 to form the first team for its new Soft Tissue and Oncology Service.

ORAL TUMOURS ARE REGULARLY ENCOUNTERED in dogs and cats and our ability to treat them has increased over the last few decades. Although many oropharyngeal tumours are best treated with a multi-modal approach, including various combinations of surgery, radiotherapy, chemotherapy and immunotherapy, surgery remains the mainstay of their treatment.

Tumour biologyLike for other cancers, tumour biology is the main determinant of prognosis. Only a few tumour types constitute the vast majority of tumours encountered.

In dogs, the most frequently encountered malignant tumours of the oral cavity are malignant melanomas (MM; 31 to 42% of cases), squamous cell carcinomas (SCC; 17 to 25% of cases), fibrosarcomas (FSA; 7.5 to 25% of cases) and osteosarcomas (OSA; 6 to 18% of cases).

In cats, the most common oropharyngeal tumours are SCC (75% of cases) and FSA (13 to 17% of cases).

Very schematically, all malignant tumours in dogs tend to be locally-invasive and require wide resection. In one study, 37 out of 120 (31%) malignant oral tumours recurred after surgical excision, with recurrence being most common with FSA (54% of cases) and least common with SCC (17% of cases).1

Malignant melanomas recurred in 27% of cases, but had the highest metastatic rate (30%). Even higher metastatic rates (50-80%) for MM have been reported previously.

In one recent study, nine of 13 dogs (69%) with MM had metastasis to locoregional lymph nodes.2 Fibrosarcomas, OSAs and SCCs had metastatic rates of 21, 22% and 3%, respectively.1 One- and two-year

survival rates were respectively 50% and 50% for SCC, 29% and 12% for FSA, 9% and 0% for OSA and 5% and 0% for MM.1 Prognostic factors for outcome with

malignant oral tumours treated by curative-intent surgery include tumour type, completeness of resection, tumour size and patient age.1

Local recurrence is

a major negative prognostic factor, influenced by tumour type, size and location, as well as by completeness of surgical excision. Wide resections, including portions of the underlying bone(s), are therefore indicated for treatment of malignant oral tumours. How wide is wide enough depends on the tumour type and size.

Tumour stagingTumour staging is a crucial step in the management of oral tumours. It involves advanced imaging to determine the location, extension and invasion of the primary tumour (T staging), imaging, mapping and biopsy of the locoregional lymph nodes (N staging) and imaging to assess the presence of distant metastasis (M staging).

Over the last few years, it has appeared that the route of lymphatic drainage of the oral cavity is complex and hardly predictable. One study of 31 dogs with oral tumours which had their mandibular and retropharyngeal lymph node extirpated bilaterally showed that 62% of metastatic tumours would spread to contralateral lymph nodes, with 8% spreading exclusively contralaterally.2

The aspect of lymph nodes cannot reliably be used to determine the usefulness of taking biopsies from them: a study evaluating 100 dogs with oral malignant melanoma showed that lymph node palpation and size are not reliable indicators (40% of normal-sized lymph nodes were positive for

metastasis) of lymph node metastasis and that cytology or histology was required for accurate staging.3 In another study involving 37 dogs and seven cats, clinical examination of the lymph node also appeared poorly correlated with their metastatic status.4

This evidences the importance of sampling the first lymph node (“sentinel” lymph node) on the lymphatic route of drainage of the tumour. The determination of the location of this sentinel lymph node is the objective of lymph node mapping techniques (Figure 1), increasingly used in veterinary oncology.5,6

Once identified, the sentinel lymph node is best examined after excisional biopsy (typically performed at the time of surgery), although in one study, cytological examination of lymph nodes for tumour invasion appeared 100% sensitive and 96% specific, showing that fine-needle aspiration is an accurate diagnostic tool for lymph

node metastasis evaluation.4

SurgeryAs discussed previously, wide surgical resection of malignant oral tumours remains the mainstay of their treatment. However, many tumours will be best treated by a multi-modal approach combining surgery with various combinations or neoadjuvant and adjuvant chemotherapy, radiotherapy, and immunotherapy. Only surgery will briefly be discussed here.

Local conditions of the oral cavity (limited availability in loose soft tissues, constant movements, bacterial charge) make wide oral resections and reconstructions often challenging. A few technical specificities, such as avoiding the use of electrocautery to cut mucosal surfaces and double-layer closures, however, limit the risk of complications. Brisk haemorrhage

continued on page 18

Recommended